₹1,580.45
+86.55 (+5.79%)
As of 21 Sept 2026, Concord Biotech Ltd share price is ₹1,580.45. The stock opened at ₹1,580.45 and had closed at ₹1,493.90 the previous day. Over the last 52 weeks, the stock has recorded a low of ₹987.05 and a high of ₹1,702.10. In terms of performance, Concord Biotech Ltd share price has increased by 36.75% over the past six months and has decreased by 7.85% over the last year.
CONCORDBIO Stock Price Chart
Concord Biotech Ltd Overview
Market cap₹15,629 Crs
Volume20,325
Prev. Close₹1,493.90
Year range₹987.05 - ₹1,702.10
ISININE338H01029
About CONCORDBIO
Concord Biotech engaged in the business of manufacturing and trading in pharmaceutical products.
Concord Biotech Ltd Historical Performance
1 Month Return-4.65%
6 Month Return30.88%
3 Year Return48.91%
3 Month Return11.32%
1 Year Return-9.78%
5 Year Return-
Concord Biotech Ltd Fundamentals
ROCE(TTM)17.41%
P/E Ratio (TTM)55.43
P/B Ratio7.74
Debt to Equity0.00
ROE13.03%
EPS (TTM)27.18
Dividend Yield0.51%
Book Value193.06
Profit Margin25.58%
Operating Margin29.48%
Concord Biotech Ltd Financials
| Indicator | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Revenue | 1,107.80 | 1,244.54 | 1,050.72 | 888.48 | 736.35 |
| EBITDA | 425.99 | 550.78 | 465.33 | 378.59 | 296.69 |
| Net Profit | 263.27 | 372.96 | 304.73 | 238.13 | 178.57 |
| EPS | 25.17 | 35.65 | 29.13 | 22.76 | 187.76 |
Concord Biotech Ltd Technical Analysis
| Indicator | Value |
|---|---|
| Support 1 (S1) | 1,462.53 |
| Resistance 1 (R1) | 1,521.63 |
| Pivot Point | 1,490.27 |
Concord Biotech Ltd Dividend History
| Ex Date | Dividends Date | Record Date | Dividend Type | Dividend Details |
|---|---|---|---|---|
| 24-Jul-2026 | 29-May-2026 | 24-Jul-2026 | Final | ₹7.55 |
| 03-Sep-2025 | 29-May-2025 | 03-Sep-2025 | Final | ₹10.70 |
| 21-Jun-2024 | 23-May-2024 | 22-Jun-2024 | Final | ₹8.75 |
CONCORDBIO Key Leadership Details
Last Updated: Mar 2026
| Name | Position |
|---|---|
| SUDHIR JAIRAM VAID | Chairman |
| ANKUR VAID | Managing Director & Chief Executive Officer |
| Ravi Kapoor | Non Executive Independent Director |
Concord Biotech Ltd Peer Comparison
| Company | Price | M.Cap (Cr) | P/E (TTM) | ROE (TTM) |
|---|---|---|---|---|
| Sun Pharmaceutical Industries LtdSUNPHARMA | ₹1,872.50+1.92% | ₹4,19,727.66 | 38.32 | 13.74% |
| Divis Laboratories LtdDIVISLAB | ₹9,384.50+0.10% | ₹1,67,235.91 | 67.46 | 15.32% |
| Torrent Pharmaceuticals LtdTORNTPHARM | ₹4,964.00+2.56% | ₹1,46,951.32 | 64.68 | 25.49% |
Disclaimer
The information provided on this page is for informational purposes only and should not be construed as investment advice, recommendation, or solicitation to buy or sell any securities or financial pr...
Frequently Asked Questions
- The share price of Concord Biotech Ltd today is ₹1,580.45 on NSE and ₹1,580.45 on BSE.
- The 52-week high of Concord Biotech Ltd is ₹1,702.10, while the 52-week low is ₹987.05.
- The current market capitalisation of Concord Biotech Ltd is approximately ₹15,629 crore.
- The P/E (Price-to-Earnings) ratio of Concord Biotech Ltd is 40.52. The ratio may vary with changes in the share price and earnings.
- The P/B (Price-to-Book) ratio of Concord Biotech Ltd is 6.90. It compares the company’s market value with its book value and can provide an indication of how the market values the company relative to its net assets.
- To buy Concord Biotech Ltd shares, you first need to open a demat account before you can place an order. Here's the process:
• Open a demat account online using your PAN, Aadhaar and bank details.
• Add funds to your trading account via UPI or net banking.
• Search for CONCORDBIO on TradeMobi or the Anand Rathi web platform.
• Place your order
• Track your holdings in the portfolio section. - Over the past 3 years, Concord Biotech Ltd has delivered a return of approximately 48.91%. This return is based on the change in the share price over the specified period and may differ depending on the measurement date. Past performance does not guarantee future returns.
- The shareholding pattern of Concord Biotech Ltd comprises different categories of shareholders. As of Jun 2026, the shareholding is approximately 44.08% promoters, 3.13% FIIs, 9.36% DIIs, and 8.23% public shareholders.
Download TradeMobi App
- Real-Time Market Data
- Advanced Trading Tools
- Expert-Backed Research
